MSB 3.21% $1.13 mesoblast limited

Ann: 83% Survival in COVID-19 ARDS Patients with Remestemcel-L, page-797

  1. 7,655 Posts.
    lightbulb Created with Sketch. 6934
    Guys,

    Read these two articles. Cytokine storms. Evident in MERS, SARS, COVID-19, ARDS, blood clots, heart failure, etc, etc. Its far more complicated than these articles, but they are a good introduction for the lay person. Combined with a bit of biological investigation into how the COVID-19 virus infects ACE-2 cells (which are evident in organs all over the body, not just your lings) and fighting cytokine storms seems an obvious root to take with COVID-19.

    I may be naively hoping for a one size fits all treatment from MSB, but even it it only gets used for ARDS related illnesses arising from COVID-19 (I am desperately hoping it does and then the medical industry begins to investigate wider applications) it is a screaming buy if the recent results get translated into bigger samples (I believe they will as do most of you).

    https://www.sciencemag.org/news/2020/04/how-does-coronavirus-kill-clinicians-trace-ferocious-rampage-through-body-brain-toes#

    https://www.knowablemagazine.org/article/health-disease/2020/what-cytokine-storm

    Let the day traders, shorters and rampers debate stock levels and stick to the fundamentals. I missed a crazy selling opportunity via index put options (I was at least short futures) when Korea blew up (this was not a black swan event but a white swan event - predictable) I am not missing the possible rally back on a Aussie company.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.